Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvespimycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 16/20 | 0.84 |
| ▸ | HSP90AB1 known ✓ | P08238 | 4/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvespimycin SCHEMBL13403878 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449725 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL16226150 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL14418059 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL28195 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449728 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL16226152 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL13928049 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL21250611 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449716 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-8741578-B2 | Methods of detecting chronic lymphocytic leukemia with Hsp90 and ZAP-70 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741578-B2 | Methods of detecting chronic lymphocytic leukemia with Hsp90 and ZAP-70 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| US-20100279995-A1 | Novel Ansamycin Derivatives | GUIBLIN ALEXANDER R | 2010-11-04 | — | — | US | disclosed |
| US-20100210597-A1 | C21-Deoxy Ansamycin Derivatives as Antitumor Agents | MOSS STEVEN | 2010-08-19 | — | — | US | disclosed |
| US-20100063020-A1 | ORAL PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | CONFORMA THERAPEUTICS CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20100063020-A1 | ORAL PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | CONFORMA THERAPEUTICS CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20090238880-A1 | PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | CONFORMA THERAPEUTICS CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090238880-A1 | PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | CONFORMA THERAPEUTICS CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20080280878-A1 | Methods and Compositions for Treating Chronic Lymphocytic Leukemia | CONFORMA THERAPEUTICS CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-20080280878-A1 | Methods and Compositions for Treating Chronic Lymphocytic Leukemia | CONFORMA THERAPEUTICS CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-20080193928-A1 | Methods and Compositions for Modulating Apoptosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193928-A1 | Methods and Compositions for Modulating Apoptosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279995-A1 | Novel Ansamycin Derivatives | BCL6, BCL3, BCL6B | HSP90AA1 333/4885HSP90AB1 245/4885ERBB2 1580/4885 |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | HSP90AA1 14/4885HSP90AB1 31/4885ERBB2 338/4885 |
| US-20100063020-A1 | ORAL PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | SMPD1, SMPD4, SMPD2 | HSP90AA1 3032/4885HSP90AB1 2921/4885ERBB2 3475/4885 |
| US-20090238880-A1 | PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME | PLTP, PHOSPHO1, PNLIP | HSP90AA1 2291/4885HSP90AB1 2022/4885ERBB2 3219/4885 |
| US-20100210597-A1 | C21-Deoxy Ansamycin Derivatives as Antitumor Agents | SLC7A1, BCL6, SLC1A5 | HSP90AA1 434/4885HSP90AB1 362/4885ERBB2 695/4885 |
| US-20080280878-A1 | Methods and Compositions for Treating Chronic Lymphocytic Leukemia | HSP90B1, MCL1, CDC37 | HSP90AA1 7/4885HSP90AB1 6/4885ERBB2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.